Clinical Trial Update: Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether urodilatin with mannitol can prevent nephrotoxicity in bone marrow transplant patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Renal Failure

Drugs mentioned

• Mannitol (mannitol)
• Urodilatin (urodilatin)

Snippet

Sponsor: Rocky Mountain Cancer Centers | Conditions: Renal Dysfunction, Acute Renal Failure | Phase 2 | Status: COMPLETED